



1000

DT06 Rec'd PCT/PTO

13 AUG 2002

Receipt

Attorney's Docket No.: 06275-288001 / SAD/AFG/Z70390/UST

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John E. N. Morten

Art Unit : 1643

Serial No. : 09/787,295

Examiner : Unknown

Filed : March 16, 2001

Title : POLYMORPHISMS IN THE HUMAN ALPHA4 INTEGRIN SUBUNIT GENE,  
SUITABLE FOR DIAGNOSIS AND TREATMENT OF INTEGRIN LIGAND  
MEDIATED DISEASES

Commissioner for Patents

Washington, D.C. 20231

#13

CD

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Please correct the Filing Receipt for the above-referenced application by amending the inventor's name "John EN Morten" to read --**John E.N. Morten**--. This correction will reflect the name of the inventor as indicated by his signature on the Declaration and Power of Attorney, a copy of which is enclosed. Please supply a corrected Filing Receipt to the undersigned. For your convenience, the enclosed copy of the original Filing Receipt highlights the desired change in red ink.

COPY OF PAPERS  
ORIGINALLY FILED

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

8/8/02

Signature

Carla L. O'Neil

Typed or Printed Name of Person Signing Certificate

Applicant : John E. N. Morten  
Serial No. : 09/787,295  
Filed : March 16, 2001  
Page : 2


Attorney's Docket No.: 06275-  
288001 / SAD/AFG/Z70390/UST

No fee is believed to be due. If, however, there are any charges or credits, please apply them to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

Aug 6, 2002

  
Janis K. Fraser, Ph.D., J.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

SEP 09 2002

9901



## UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/787,295	03/16/2001	1643	1450	P 277177		13	7

00909  
PILLSBURY WINTHROP LLP  
1600 TYSONS BOULEVARD  
MCLEAN, VA 22102

CONFIRMATION NO. 8239

## FILING RECEIPT



\*OC000000007389653\*

Date Mailed: 01/31/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

John ~~EN~~ Morten, Macclesfield Cheshire, UNITED KINGDOM;  
John E. N. Morten

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/GB99/03071 09/15/1999

## Foreign Applications

UNITED KINGDOM 9820339.1 09/18/1998  
UNITED KINGDOM 9824506.1 11/10/1998

Projected Publication Date: Not Applicable, filed prior to November 2000

Non-Publication Request: No


Early Publication Request: No

## Title

Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases

## Preliminary Class

435



---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

FOR UTILITY/DESIGN  
CI/PCT NATIONAL/PLANT  
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL  
DECLARATIONS

RULE 63 (37 C.F.R. 1.53)  
DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PW  
FORM  
Z70390/US1

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED POLYMORPHISMS IN THE HUMAN ALPHA4 INTEGRIN SUBUNIT GENE, SUITABLE FOR DIAGNOSIS AND TREATMENT OF INTEGRIN LIGANT

the specification of which (CHECK applicable BOX(ES)) MEDIATED DISEASES  
X ☐ is attached hereto.  
BOX(ES) → B. ☐ was filed on \_\_\_\_\_ as U.S. Application No. \_\_\_\_\_ /  
→ C. ☒ was filed as PCT International Application No. PCT/ GB99 /03071 on 15.09.1999

and (if applicable to U.S. or PCT application) was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

**PRIOR FOREIGN APPLICATION(S)**

Number	Country	Day/MONTH/Year Filed
9820339.1	GB	19.09.1998
9824506.1	GB	10.11.1998

Date first Launched / Patented  
open or Published ☒ Granted

Priority NOT Claimed

If more prior foreign applications, X box at bottom and continue on attached page.

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(e) or 120 and/or 365(c) of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

**PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S)**  
Application No. (series code/serial no.) \_\_\_\_\_ Day/MONTH/Year Filed \_\_\_\_\_

Status \_\_\_\_\_  
pending, abandoned, patented

Priority NOT Claimed

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Winthrop LLP, Intellectual Property Group, telephone number (202) 861-3000 (to whom all communications are to be directed), and persons of that firm who are associated with USPTO Customer No. 909 (see below label) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete from that Customer No. names of persons no longer with their firm, to add new persons of their firm to that Customer No., and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or an attorney of that Firm in writing to the contrary.

RECEIVED

COPY OF PAPERS  
ORIGINALLY FILED



00909

SEP 09 2002

TECH CENTER 1600/2900

Date: 8<sup>th</sup> February 2001

(1) INVENTOR'S SIGNATURE: John E. N. Morten

Name	JOHN	EN	MORTEN
	First	Middle Initial	Family Name
Residence	Macclesfield	Cheshire	United Kingdom
	City	State/Foreign Country	Country of Citizenship
Mailing Address	Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom		
(include Zip Code)			

(2) INVENTOR'S SIGNATURE:

Date:

Name			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Mailing Address			
(include Zip Code)			

☐ FOR ADDITIONAL INVENTORS see attached page.

☐ See additional foreign priorities on attached page (incorporated herein by reference).

Atty. Dkt. No. P

(M#)